PR Newswire Asia's news > Health Care/Hospital

 < Previous page   |   Title only   |   Print    Next page > 
     
Samsung Biologics Reports Second Quarter 2026 Financial Results
Recorded Q2'26 revenue of KRW 1,321 billion and operating profit of KRW 586 billion Delivered stable business performance through continued disciplined execution Expanded global presence while advancing ...
2026-07-23T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
HKEY-AI4AI-Atlas™ 1.0: HKeyBio Uses AI to Curate Autoimmune Model Datasets
HKEY-AI4AI-Atlas™ 1.0 uses AI-assisted dataset curation to support model selection, endpoint design and cross-species interpretation ...
2026-07-22T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Targeting the $100 Billion Market: Insilico Medicine Nominates AI-driven Novel PCC ISM9528 for Pain Management
AI-Driven New Mechanism Discovery: Targeting an undisclosed novel mechanism empowered by PandaOmics, the PCC ISM9528 offers a potential first-in-class, brain -penetrant, non-opioid solution for pain ...
2026-07-22T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Ribo Discloses Positive Data from Vortosiran Phase 2a Trial - World's First Clinical Data on siRNA-Mediated FXI Inhibition Following Multiple Dosing in Patients with Coronary Artery Disease
SHANGHAI and MOLNDAL, Sweden , July 22, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd.  (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo") ...
2026-07-22T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Tikva Allocell Closes $8 Million Series A Financing to Advance Engineered EBV-Specific T-Cell Therapy for Solid Tumors
Funding will support completion of IND-enabling activities and planned year-end IND submission for TAVST01, Tikva's lead off-the-shelf CAR-T candidate targeting B7-H3-positive solid tumors ...
2026-07-22T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
LSBF and University of Roehampton Expand Healthcare Education with LSBF Singapore Campus's New School of Health Sciences
SINGAPORE , July 22, 2026 /PRNewswire/ -- London School of Business & Finance (LSBF) Singapore Campus has announced the launch of its School of Health Sciences in 2026, marking a significant milestone ...
2026-07-22T    Banking/Financial Service   Biotechnology   Education   Health Care/Hospital 
NOVI Health Named Wellness Partner for Visa Infinite's Reimagined Premium Ecosystem Across Asia Pacific
Singapore-founded longevity brand joins Visa Infinite as a premium health partner for Asia Pacific, reflecting a new era where healthspan is as valuable as status. ...
2026-07-22T    Health Care/Hospital 
Gene Solutions Showcases Global Evidence and Responsible Innovation in Prenatal and Women's Genomic Health at ISPD 2026
As a Premier Partner, Gene Solutions presented Asia-led real-world evidence from large-scale NIPT-integrated carrier screening, alongside advances in AI-enabled pregnancy-risk assessment and minimally ...
2026-07-22T    Biotechnology   Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
NSG Bio Accelerates Breakthrough Biotech Innovation in Singapore
New initiative under NSG Bio Tomorrow will support promising startups developing next-generation approaches in respiratory and neonatal care ...
2026-07-22T    Biotechnology   Computer/Electronics   Health Care/Hospital   Medical/Pharmaceuticals 
China Pharma Holdings, Inc. Comments on Unusual Market Activity
HAIKOU, China , July 22, 2026 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma" or the "Company"), a fully-integrated specialty pharmaceuticals ...
2026-07-22T    Banking/Financial Service   Health Care/Hospital   Medical/Pharmaceuticals 
 < Previous page    Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.